EVMN News
Archived Headlines
- US IPO Week Ahead: Beta Technologies leads flurry of debuts as shutdown rolls on 10/31/25
- Chronic inflammatory disease biotech Evommune sets terms for $150 million IPO 10/17/25
- US IPO Weekly Recap: 6 IPOs debut, pipeline grows, despite government shutdown 10/10/25
- Chronic inflammatory disease biotech Evommune files for a $100 million IPO 10/09/25
Biotech IPOs are back: Why 2026 could mark a hot year for the sector
After a period of uneven performance, the biotech IPO market is beginning to show signs of renewed momentum. On Monday, radiopharmaceutical oncology biotech Aktis Oncology (AKTS) launched a $200 million IPO; two days later, the company upsized the deal by 50%...read more
US IPO Weekly Recap: Beta Technologies leads 6 deal week to open November
Six IPOs debuted this week, raising a combined $1.8 billion. Four SPACs also listed. One IPO and seven SPACs submitted initial filings. Leading the pack, electric aircraft manufacturer Beta Technologies (BETA) priced its upsized IPO above the range to raise...read more
Chronic inflammatory disease biotech Evommune prices IPO at $16 midpoint
Evommune, a Phase 2 biotech developing therapies for chronic inflammatory diseases, raised $150 million by offering 9.4 million shares at $16, the midpoint of the range of $15 to $17. At pricing, Evommune commands a fully diluted market value of $544 million. ...read more
Renaissance Capital's October IPO Market Update
The long-awaited IPO pickup lost some of its steam in October, as the US government shutdown disrupted timelines and delayed deal activity. Twenty-two IPOs raised a combined $3.2 billion, in line with the 10-year historical average by deal count (21) but well...read more